BIOCRYST PHARMACEUTICALS INC (BCRX) is a publicly traded company in the Unknown sector. Across all available filings, 51 corporate insiders have executed 974 transactions totaling $89.2M, demonstrating a bearish sentiment with -$47.6M in net insider flow. The most recent transaction on Dec 22, 2025 involved a transaction of 10,091 shares valued at $50.9K.
No significant insider buying has been recorded for BCRX in the recent period.
No significant insider selling has been recorded for BCRX in the recent period.
Based on recent SEC filings, insider sentiment for BCRX is bearish with an Insider Alignment Score of 23/100 and a net flow of -$47.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at BIOCRYST PHARMACEUTICALS INC (BCRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 51 insiders are actively trading BCRX stock, having executed 974 transactions in the past 90 days. The most active insider is Julian Baker (Executive), who has made 27 transactions totaling $21.4M.
Get notified when executives and directors at BCRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | K. Gayer Charles | Executive | Option Exercise | 10,091 | $5.04 | $50.9K | |
| Dec 22, 2025 | K. Gayer Charles | Executive | Option Exercise | 14,142 | $3.22 | $45.5K | |
| Dec 22, 2025 | K. Gayer Charles | Executive | Option Exercise | 50,000 | $5.51 | $275.5K | |
| Dec 22, 2025 | P. Barnes Alane | Executive | Sale | 21,773 | $7.65 | $166.6K | |
| Dec 19, 2025 | K. Gayer Charles | Executive | Payment | 11,477 | $7.41 | $85.0K | |
| Dec 19, 2025 | P. Barnes Alane | Executive | Payment | 16,902 | $7.41 | $125.2K | |
| Dec 19, 2025 | P. Stonehouse Jon | Executive | Payment | 61,793 | $7.41 | $457.9K | |
| Dec 18, 2025 | P. Stonehouse Jon | Executive | Gift | 10,000 | $N/A | $0 | |
| Dec 18, 2025 | P. Stonehouse Jon | Executive | Gift | 10,000 | $N/A | $0 | |
| Dec 18, 2025 | P. Stonehouse Jon | Executive | Gift | 20,000 | $N/A | $0 | |
| Dec 17, 2025 | Ghias Babar | Executive | Award | 121,700 | $N/A | $0 | |
| Dec 17, 2025 | P. Barnes Alane | Executive | Award | 121,700 | $N/A | $0 | |
| Dec 17, 2025 | K. Gayer Charles | Executive | Award | 471,000 | $N/A | $0 | |
| Dec 15, 2025 | P. Barnes Alane | Executive | Sale | 21,210 | $7.65 | $162.3K | |
| Dec 12, 2025 | P. Stonehouse Jon | Executive | Payment | 27,368 | $7.57 | $207.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 313 | $68.4M | 62.1% |
Purchase(P) | 103 | $20.8M | 18.9% |
Exercise(M) | 209 | $13.8M | 12.5% |
Payment(F) | 117 | $5.4M | 4.9% |
Award(A) | 213 | $1.1M | 1.0% |
Gift(G) | 16 | $607.4K | 0.6% |
Other(J) | 3 | $12 | 0.0% |
Insider selling pressure at BIOCRYST PHARMACEUTICALS INC has increased, with 51 insiders executing 974 transactions across all time. Total sales of $68.4M significantly outpace purchases of $20.8M, resulting in a net outflow of $47.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.